摘要
目的本研究通过收集原发性肝细胞癌(hepatocellular carcinoma,HCC)患者的临床资料,并检测癌及癌旁组织中Claudin-3和Snail蛋白的表达,探讨Claudin-3和Snail蛋白与肝癌患者临床病理特征与预后的关联。方法收集根治性切除的肝细胞癌病例患者资料,利用免疫组织化学的方法检测82例HCC组织及60例癌旁组织中Snail、Claudin-3蛋白的表达。采用Kaplan-Meier法进行生存分析,应用Cox比例风险模型进行多因素回归分析。结果肝癌组织中Snail蛋白阳性表达69.47%,高于癌旁组织,差异有统计学意义(P=0.001);Claudin-3阳性表达47.61%,低于癌旁组织,差异有统计学意义(P=0.002);两者的表达呈负相关(r=-0.430,P<0.01);Snail蛋白在HCC中阳性表达明显高于癌旁组织,在病理分期、微血管侵犯相关方面差异有统计学意义(P<0.05);在Cox多因素回归分析中,Snail、Claudin-3的表达是HCC患者生存的独立危险因素(P<0.05)。结论Snail与Claudin-3蛋白与HCC的发生、侵袭有一定的关联性。进行HCC患者Snail、Claudin-3蛋白的联合检测,在临床实践中对HCC患者病理学特征与预后的判断具有重要的提示作用。
Objective This study aimed to investigate the relationship between the expression of Claudin-3 or Snail and the clinical pathology and prognosis in the hepatocellular carcinoma（ HCC） patients by detecting the expression of Claudin-3 and Snail in the HCC and liver cancer-adjacent tissues. Methods Snail and Claudin-3 were detected in cases of 60 liver cancer-adjacent tissues and 82 cases of HCC by using immunohistochemical technique. The postoperative prognostic factors were assessed by univariate Kaplan-Meier analysis and a multivariate Cox proportional hazard model. Results Snail positive expression was 69. 47% in HCC and was significantly higher than liver cancer-adjacent tissues（ P = 0. 001）. Claudin-3 proteins positive expression were 47. 61% in HCC and were significantly lower than liver cancer-adjacent tissue（ P = 0. 002）. The expression of Snail and Claudin-3 was negatively correlated（ r =-0. 430,P〈0. 01）. Snail positive expression in HCC was significantly higher than liver cancer-adjacent tissues,and the difference was statistically significant in microvascular invasion and stages of pathology tumor lymph node metastasis（ P〈0. 05）. Multivariate analysis by using Cox regression model identified that Snail and Claudin-3 were independent prognostic factors of HCC（ P〈0. 05）. Conclusion The correlation between the Snail or Claudin-3 and the occurrence and invasion in HCC were exhibited. The combined detection of Snail and Claudin-3 protein in HCC patients might be an important pathological and prognosis biomarker in HCC patients.
作者
申燕军
陈京龙
车娟娟
王婧
曹邦伟
Shen Yanjun;Chen Jinglong;Che Juanjuan;Wang Jing;Cao Bangwei(Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China)
出处
《首都医科大学学报》
CAS
北大核心
2018年第3期393-397,共5页
Journal of Capital Medical University
基金
北京市自然科学基金(7172081)~~
